Rapport Therapeutics Preps KOL Event Ahead of Bipolar Mania Trial Readout
Event summary
- Rapport Therapeutics to host virtual KOL event on September 22, 2026, featuring experts Mauricio Tohen and Gary Sachs.
- Event to discuss unmet needs in bipolar mania treatment and RAP-219 clinical program.
- RAP-219 is a TARPγ8-specific AMPA receptor negative allosteric modulator in Phase 2 trial for bipolar mania.
- Topline data from Phase 2 trial expected in October 2026.
- Company highlights potential first-in-class positioning for RAP-219 in bipolar mania.
The big picture
Rapport Therapeutics is positioning itself at the forefront of precision medicine for neurological disorders with its RAP-219 program. The upcoming KOL event and imminent trial readout highlight the strategic focus on addressing unmet needs in bipolar mania treatment. The company's approach of targeting specific brain regions with its TARPγ8-specific AMPA receptor modulator could differentiate it in a competitive landscape if clinical data supports its potential.
What we're watching
- Clinical Data Impact
- How October 2026 topline data from the Phase 2 trial will influence RAP-219's development path and investor sentiment.
- Market Differentiation
- Whether RAP-219's targeted mechanism can position it as a first-in-class treatment for bipolar mania.
- Pipeline Potential
- The pace at which Rapport Therapeutics can advance RAP-219 into additional indications beyond bipolar mania.
Related topics